Effect of timing of administration on lipid-lowering efficacy of statins-meta-analysis

被引:0
|
作者
Wang, Chang [1 ]
Quan, Yawen [2 ]
Wang, Linfeng [3 ]
Li, Gang [1 ,4 ]
机构
[1] North China Univ Sci & Technol, Grad Sch, Tangshan, Hebei, Peoples R China
[2] Hebei Med Univ, Grad Sch, Shijiazhuang, Hebei, Peoples R China
[3] Hebei North Univ, Grad Sch, Zhangjiakou, Hebei, Peoples R China
[4] Hebei Gen Hosp, Inst Geriatr Dis, Div Cardiol, Shijiazhuang 050000, Hebei, Peoples R China
基金
中国国家自然科学基金;
关键词
Statins; Low-density lipoprotein cholesterol; Cholesterol; Half-life; Duration of medication; Medication morning and evening; CONTROLLED-RELEASE SIMVASTATIN; OPTICAL COHERENCE TOMOGRAPHY; ACUTE MYOCARDIAL-INFARCTION; SERUM-CHOLESTEROL; EVENING INTAKE; DOUBLE-BLIND; SAFETY; ATORVASTATIN; RATIONALE; THERAPY;
D O I
10.1007/s00228-023-03575-4
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background To investigate the effect of timing of statin administration on lipid-lowering efficacy.Methods Computer searches of Pubmed, Embase, Cochrane Library, and Web of Science databases from 1986 to 2023. The impact of administration time on the lipid-lowering efficacy of statin drugs was investigated. Following a series of screenings, a funnel plot was constructed to assess its symmetry, and Egger and Beggar tests were conducted using StataMP-64 to evaluate publication bias. Meta-analysis was performed using RevMan 5.3 to combine MD values.Results Fifteen papers (1352 participants) met and included the criteria. The results of the meta-analysis showed that the effect of morning and evening administration time on plasma triglycerides (TG) (P > 0.05) and plasma high-density lipoprotein cholesterol (HDL-C) (P > 0.05) was not statistically significant. There were significant reductions in total cholesterol (TC) (MD: 0.15 mmol/L, 95% CI: 0.06-0.23, P < 0.01) and low-density lipoprotein cholesterol (LDL-C) (MD: 0.10 mmol/L, 95% CI: - 0.00-0.20, P < 0.01) in the night group. According to the analysis results of the half-life of statins, only short half-life statins showed that nocturnal administration reduced LDL-C (MD: 0.21 mmol/L, 95% CI: 0.09-0.33, P < 0.01) and TC (MD: 0.32 mmol/L, 95% CI: 0.18-0.46, P < 0.01) levels and was better than morning administration. Long half-life statins did not show significant differences. In addition, the administration time of short half-life statins also showed that night administration tended to reduce TG (MD: 0.16 mmol/L, 95% CI: 0.02-0.30, P < 0.05) levels. In subgroup analysis according to clinical factors in patients aged < 55 years, there was no significant difference in the timing of administration between the two groups; the efficacy of statins in lowering lipids in patients aged >= 55 years was significantly different in the TC group (P < 0.01) and LDL-C group (P < 0.01). The administration time of the TC group (P < 0.05) and LDL-C group (P < 0.05) in the Americas, Europe, and Asian groups was significantly different for statins. In addition, the American group also showed that the administration time of the two groups was significantly different from the TG group (P < 0.05).Conclusion The efficacy of administering short half-life statin drugs at night in reducing plasma levels of TC, LDL-C, and TG surpasses that of morning administration. However, this study did not determine the impact of timing of statin administration in patients taking long half-life statins on the efficacy of the medication. Therefore, it is recommended to consider patient adherence when. The study was registered on PROSPERO (International Prospective Register of Systematic Reviews) as CRD42022372105 (available at https://www.crd.york.ac.uk/prospero/).
引用
收藏
页码:1641 / 1656
页数:16
相关论文
共 50 条
  • [31] Lipid-lowering therapy with statins, a new approach to antiarrhythmic therapy
    Tamargo, Juan
    Caballero, Ricardo
    Gomez, Ricardo
    Nunez, Lucia
    Vaquero, Miguel
    Delpon, Eva
    PHARMACOLOGY & THERAPEUTICS, 2007, 114 (01) : 107 - 126
  • [33] Lipid-Lowering Therapy and Intracerebral Hemorrhage Risk: Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
    Cuesta, Sanz Borja E.
    Saver, Jeffrey L.
    STROKE, 2021, 52
  • [34] Lipid-Lowering Therapy and Hemorrhagic Stroke Risk Comparative Meta-Analysis of Statins and PCSK9 Inhibitors
    Sanz-Cuesta, Borja E.
    Saver, Jeffrey L.
    STROKE, 2021, 52 (10) : 3142 - 3150
  • [35] Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis
    Hsu, Hsin-Yin
    Lin, Chien-Ju
    Lee, Yu-Shan
    Wu, Ting-Hui
    Chien, Kuo-Liong
    BMC CARDIOVASCULAR DISORDERS, 2020, 20 (01)
  • [36] Efficacy of more intensive lipid-lowering therapy on cardiovascular diseases: a systematic review and meta-analysis
    Hsin-Yin Hsu
    Chien-Ju Lin
    Yu-Shan Lee
    Ting-Hui Wu
    Kuo-Liong Chien
    BMC Cardiovascular Disorders, 20
  • [37] Comparative efficacy and safety of lipid-lowering agents in patients with hypercholesterolemia: A frequentist network meta-analysis
    Zhao, Zonglei
    Du, Song
    Shen, Shuxin
    Luo, Ping
    Ding, Shoukun
    Wang, Guanggong
    Wang, Lixia
    MEDICINE, 2019, 98 (06)
  • [38] Genetic effects on efficacy of lipid-lowering drugs
    Brown, William Virgil
    Brown, Alan S.
    Ference, Brian A.
    Toth, Peter P.
    Underberg, James A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2017, 11 (05) : 1112 - 1117
  • [39] Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins
    Chan, D. K. Y.
    O'Rourke, F.
    Shen, Q.
    Mak, J. C. S.
    Hung, W. T.
    ACTA NEUROLOGICA SCANDINAVICA, 2011, 124 (03): : 188 - 195
  • [40] Effect of lipid-lowering efficacy of ezetimibe coadministered with ongoing simvastatin treatment
    Zeynapu, A. A.
    Bubnova, M. G.
    Perova, N. V.
    ATHEROSCLEROSIS SUPPLEMENTS, 2007, 8 (01) : 206 - 206